The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways
暂无分享,去创建一个
[1] Yen-Shen Lu,et al. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives , 2021, Therapeutics and clinical risk management.
[2] Khanh B. Tran,et al. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK , 2021, BMC cancer.
[3] Yurong Song,et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers , 2020, Cell Death & Disease.
[4] D. Spandidos,et al. Cutaneous melanoma and the immunotherapy revolution (Review) , 2020, International journal of oncology.
[5] M. Libra,et al. Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma , 2020, Cells.
[6] M. Libra,et al. Current Perspectives in Cancer Immunotherapy , 2019, Cancers.
[7] A. Hauschild,et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. , 2019, The New England journal of medicine.
[8] Massimo Libra,et al. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium , 2018, Front. Pharmacol..
[9] T. Dragovich,et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma , 2018, OncoTargets and therapy.
[10] R. Kefford,et al. Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma , 2018, Oncogenesis.
[11] G. Madonna,et al. MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA , 2018, Front. Pharmacol..
[12] Demetrios A. Spandidos,et al. Cutaneous melanoma: From pathogenesis to therapy (Review) , 2018, International journal of oncology.
[13] M. McMahon,et al. PIK3CA‐mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation , 2017, Pigment cell & melanoma research.
[14] Bin Zhao,et al. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials , 2017, Oncotarget.
[15] D. Spandidos,et al. NF-κB inhibition is associated with OPN/MMP-9 downregulation in cutaneous melanoma , 2017, Oncology reports.
[16] M. Hall,et al. mTOR Signaling Confers Resistance to Targeted Cancer Drugs. , 2016, Trends in cancer.
[17] K. Flaherty,et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Ribas,et al. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy , 2016, Therapeutic advances in medical oncology.
[19] C. Berking,et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.
[20] J. Utikal,et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.
[21] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[22] R. Bjerkvig,et al. In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways , 2014, International journal of molecular sciences.
[23] Y. Ye,et al. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway , 2014, Drug design, development and therapy.
[24] G. Pupo,et al. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.
[25] K. Flaherty,et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] T. Gilmer,et al. Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.
[27] B. Taylor,et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF , 2012, Oncogene.
[28] J. Blenis,et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.
[29] V. Sondak,et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.
[30] T. Barber,et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. , 2000, The Journal of biological chemistry.
[31] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[32] Antoni Ribas,et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.
[33] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.